The chronic lymphocytic leukemia therapeutics market is expected to grow at a CAGR of 13.43% from 2015 to 2020. (Roche/Biogen Idec), a third-generation, humanized, and glyco-engineered anti-CD20 monoclonal antibody drug followed by Arzerra (GlaxoSmithKline Plc/Genmab AS). Pipeline drug and increasing chronic lymphocytic leukemia population globally are the major factors driving the market for new drugs. A potential limiting factor in the growth of sales for chronic lymphocytic leukemia drugs will be the major drugs going off-patent during the time period being forecasted. Patents for two drugs –Treanda by Cephalon Inc, and Campath by Eli Lilly will expire in 2015; Rituxan by Roche will lose patent in 2011. Fludara by Genzyme has a patent expiry in 2018. Arzerra by GSK will have patent expiry in 2023.

From a regional approach, North America accounts for the largest chronic lymphocytic leukemia population globally. The incidence rate and mortality rate for chronic lymphocytic leukemia are showing upward trend due to the increase in the aging population in most of the developed countries. Such an upward incidence trend can be attributed to the age risk factor of chronic lymphocytic leukemia. Males and females above 50 years of age are at high risk for chronic lymphocytic leukemia. The incidence rate and mortality rate for leukemia is showing an upswing due to the increase in the aging population in most of the developed countries. Such a trend can be attributed to the age risk factor of chronic lymphocytic leukemia. Recent studies show that males and females above 65 years of age are at high risk for chronic lymphocytic leukemia. Epidemiologic studies have found that incidence and mortality due to leukemia differ according to race and ethnicity. The incidence and mortality rates for chronic lymphocytic leukemia are higher in whites than in people of the other racial and ethnic groups due to genetic factors.

The major players in the market include Biogen Idec (U.S.), Celgene Corporation (U.S.), Cephalon Inc. (U.S.), Genmab A/S (Denmark), Genzyme Corporation (U.S.),  GlaxoSmithKline Pharmaceuticals Limited (U.K.), Genentech Inc. (U.S.) and F. Hoffmann-La Roche Ltd (Switzerland).

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services.

MarketsandMarkets covers thirteen industry verticals, including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website www.marketsandmarkets.com

Note: An email containing the Login Details and Time of the Analyst Briefing will be sent to you soon after your registration.